| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sjogren's Syndrome | 40 | 2025 | 274 | 6.610 |
Why?
|
| Sarcoidosis | 5 | 2023 | 38 | 1.360 |
Why?
|
| Lupus Erythematosus, Systemic | 15 | 2018 | 992 | 1.360 |
Why?
|
| Genetic Predisposition to Disease | 18 | 2023 | 671 | 1.260 |
Why?
|
| Spinocerebellar Ataxias | 7 | 2019 | 28 | 1.030 |
Why?
|
| HLA-DRB1 Chains | 3 | 2023 | 33 | 0.890 |
Why?
|
| Humans | 83 | 2025 | 28581 | 0.840 |
Why?
|
| African Americans | 6 | 2020 | 352 | 0.830 |
Why?
|
| Trinucleotide Repeat Expansion | 6 | 2009 | 35 | 0.810 |
Why?
|
| Salivary Glands | 6 | 2025 | 58 | 0.790 |
Why?
|
| Male | 49 | 2025 | 13771 | 0.730 |
Why?
|
| Female | 52 | 2025 | 15471 | 0.720 |
Why?
|
| Huntington Disease | 3 | 2009 | 9 | 0.690 |
Why?
|
| Genetic Testing | 4 | 2010 | 68 | 0.690 |
Why?
|
| Middle Aged | 32 | 2025 | 7310 | 0.690 |
Why?
|
| Autoantibodies | 11 | 2023 | 479 | 0.690 |
Why?
|
| Indians, North American | 5 | 2020 | 534 | 0.680 |
Why?
|
| Arthritis, Rheumatoid | 3 | 2016 | 134 | 0.680 |
Why?
|
| Transcriptome | 3 | 2021 | 214 | 0.670 |
Why?
|
| von Hippel-Lindau Disease | 3 | 2010 | 9 | 0.650 |
Why?
|
| Registries | 8 | 2021 | 393 | 0.600 |
Why?
|
| Adult | 29 | 2025 | 7922 | 0.600 |
Why?
|
| Genome-Wide Association Study | 5 | 2022 | 233 | 0.580 |
Why?
|
| Antibodies, Antinuclear | 8 | 2023 | 183 | 0.580 |
Why?
|
| Salivary Glands, Minor | 4 | 2021 | 21 | 0.560 |
Why?
|
| Mexico | 13 | 2016 | 91 | 0.550 |
Why?
|
| Case-Control Studies | 15 | 2025 | 732 | 0.530 |
Why?
|
| Diagnostic Errors | 1 | 2016 | 32 | 0.490 |
Why?
|
| Alleles | 8 | 2023 | 354 | 0.440 |
Why?
|
| Pedigree | 13 | 2019 | 155 | 0.440 |
Why?
|
| Polymorphism, Single Nucleotide | 13 | 2022 | 550 | 0.430 |
Why?
|
| Friedreich Ataxia | 4 | 2007 | 47 | 0.430 |
Why?
|
| Aged | 15 | 2025 | 5525 | 0.410 |
Why?
|
| Severity of Illness Index | 6 | 2021 | 461 | 0.400 |
Why?
|
| Smoking | 1 | 2017 | 476 | 0.390 |
Why?
|
| Phenotype | 11 | 2021 | 682 | 0.390 |
Why?
|
| Cohort Studies | 10 | 2021 | 893 | 0.370 |
Why?
|
| Genetic Linkage | 2 | 2010 | 95 | 0.340 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2025 | 111 | 0.330 |
Why?
|
| Adolescent | 10 | 2021 | 3165 | 0.320 |
Why?
|
| Germ-Line Mutation | 2 | 2010 | 31 | 0.320 |
Why?
|
| Age of Onset | 7 | 2021 | 72 | 0.310 |
Why?
|
| Program Evaluation | 1 | 2009 | 172 | 0.300 |
Why?
|
| Anticipation, Genetic | 2 | 2013 | 3 | 0.300 |
Why?
|
| Myoclonic Epilepsy, Juvenile | 5 | 2009 | 5 | 0.290 |
Why?
|
| Gene Expression Profiling | 2 | 2021 | 453 | 0.290 |
Why?
|
| Biomarkers | 7 | 2023 | 770 | 0.280 |
Why?
|
| Genes, Dominant | 2 | 2007 | 35 | 0.280 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2025 | 83 | 0.280 |
Why?
|
| DNA Repeat Expansion | 4 | 2019 | 4 | 0.270 |
Why?
|
| TATA-Box Binding Protein | 1 | 2007 | 3 | 0.270 |
Why?
|
| Fatigue | 2 | 2025 | 64 | 0.270 |
Why?
|
| Calcium Channels | 1 | 2007 | 34 | 0.270 |
Why?
|
| NADPH Oxidases | 3 | 2017 | 69 | 0.260 |
Why?
|
| Biopsy | 5 | 2019 | 207 | 0.260 |
Why?
|
| Cross-Sectional Studies | 3 | 2020 | 988 | 0.250 |
Why?
|
| Interferon Regulatory Factors | 4 | 2016 | 58 | 0.250 |
Why?
|
| DNA Mutational Analysis | 6 | 2009 | 93 | 0.250 |
Why?
|
| Hemangioblastoma | 1 | 2006 | 12 | 0.250 |
Why?
|
| Child | 7 | 2012 | 2271 | 0.250 |
Why?
|
| Sialadenitis | 2 | 2016 | 16 | 0.240 |
Why?
|
| Risk Factors | 4 | 2020 | 2111 | 0.230 |
Why?
|
| Rheumatoid Factor | 4 | 2019 | 28 | 0.230 |
Why?
|
| Cognition Disorders | 1 | 2006 | 186 | 0.220 |
Why?
|
| Ribonucleoproteins | 5 | 2019 | 154 | 0.220 |
Why?
|
| B-Lymphocytes | 2 | 2018 | 285 | 0.220 |
Why?
|
| Carrier Proteins | 2 | 2016 | 252 | 0.220 |
Why?
|
| American Native Continental Ancestry Group | 2 | 2016 | 22 | 0.210 |
Why?
|
| Nerve Tissue Proteins | 3 | 2013 | 154 | 0.210 |
Why?
|
| Gene Frequency | 6 | 2022 | 185 | 0.200 |
Why?
|
| Genotype | 8 | 2016 | 461 | 0.200 |
Why?
|
| Chromosomes, Human, X | 3 | 2017 | 38 | 0.200 |
Why?
|
| Central Nervous System Diseases | 1 | 2022 | 13 | 0.190 |
Why?
|
| Iron-Binding Proteins | 3 | 2007 | 38 | 0.190 |
Why?
|
| Mutation | 7 | 2016 | 864 | 0.190 |
Why?
|
| Tuberculosis | 1 | 2022 | 25 | 0.190 |
Why?
|
| Haplotypes | 9 | 2016 | 284 | 0.190 |
Why?
|
| Genetic Association Studies | 4 | 2017 | 115 | 0.190 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2022 | 33 | 0.180 |
Why?
|
| Immunity, Innate | 2 | 2015 | 231 | 0.180 |
Why?
|
| c-Mer Tyrosine Kinase | 1 | 2021 | 13 | 0.180 |
Why?
|
| Prognosis | 5 | 2022 | 807 | 0.180 |
Why?
|
| Mitochondria | 1 | 2025 | 396 | 0.180 |
Why?
|
| Child, Preschool | 4 | 2010 | 1167 | 0.180 |
Why?
|
| Membrane Proteins | 3 | 2016 | 485 | 0.180 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2021 | 94 | 0.170 |
Why?
|
| Serologic Tests | 2 | 2017 | 19 | 0.170 |
Why?
|
| Antibody-Producing Cells | 2 | 2018 | 15 | 0.170 |
Why?
|
| Cell Movement | 2 | 2020 | 373 | 0.170 |
Why?
|
| Sex Chromosome Aberrations | 2 | 2017 | 16 | 0.170 |
Why?
|
| Autoimmune Diseases | 3 | 2017 | 166 | 0.170 |
Why?
|
| Gene Regulatory Networks | 1 | 2021 | 78 | 0.170 |
Why?
|
| Neoplasms | 1 | 2010 | 857 | 0.170 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2020 | 59 | 0.170 |
Why?
|
| Consensus | 3 | 2017 | 75 | 0.170 |
Why?
|
| Single-Cell Analysis | 1 | 2020 | 55 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 6 | 3 | 2006 | 19 | 0.160 |
Why?
|
| Sex Chromosome Disorders of Sex Development | 2 | 2017 | 11 | 0.160 |
Why?
|
| Autoimmunity | 2 | 2021 | 158 | 0.160 |
Why?
|
| Quantitative Trait Loci | 2 | 2017 | 53 | 0.160 |
Why?
|
| Putamen | 1 | 2019 | 3 | 0.160 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 148 | 0.160 |
Why?
|
| Monocytes | 1 | 2020 | 135 | 0.160 |
Why?
|
| Gray Matter | 1 | 2019 | 24 | 0.160 |
Why?
|
| Thalamus | 1 | 2019 | 26 | 0.160 |
Why?
|
| Odds Ratio | 2 | 2017 | 236 | 0.160 |
Why?
|
| Keratoconjunctivitis Sicca | 1 | 2019 | 4 | 0.150 |
Why?
|
| Exocrine Glands | 1 | 2019 | 4 | 0.150 |
Why?
|
| Cerebellum | 1 | 2019 | 41 | 0.150 |
Why?
|
| Eye | 1 | 2019 | 36 | 0.150 |
Why?
|
| United States | 5 | 2017 | 2201 | 0.150 |
Why?
|
| Epithelial Cells | 1 | 2021 | 256 | 0.150 |
Why?
|
| Cryoglobulins | 1 | 2018 | 2 | 0.150 |
Why?
|
| Complement C4 | 1 | 2018 | 16 | 0.150 |
Why?
|
| Diagnosis, Differential | 2 | 2019 | 378 | 0.150 |
Why?
|
| Complement C3 | 1 | 2018 | 21 | 0.150 |
Why?
|
| Lymphocytes | 1 | 2019 | 90 | 0.150 |
Why?
|
| White Matter | 1 | 2019 | 90 | 0.150 |
Why?
|
| Periodontitis | 1 | 2018 | 11 | 0.140 |
Why?
|
| Lupus Erythematosus, Discoid | 1 | 2018 | 18 | 0.140 |
Why?
|
| Somatic Hypermutation, Immunoglobulin | 1 | 2018 | 16 | 0.140 |
Why?
|
| beta Karyopherins | 2 | 2016 | 13 | 0.140 |
Why?
|
| Antibodies, Anticardiolipin | 1 | 2017 | 23 | 0.140 |
Why?
|
| Mosaicism | 1 | 2017 | 13 | 0.140 |
Why?
|
| B-Cell Activating Factor | 1 | 2017 | 32 | 0.140 |
Why?
|
| Antibodies, Bacterial | 1 | 2018 | 103 | 0.140 |
Why?
|
| DNA Methylation | 2 | 2021 | 152 | 0.140 |
Why?
|
| 2',5'-Oligoadenylate Synthetase | 1 | 2017 | 9 | 0.140 |
Why?
|
| Terminology as Topic | 1 | 2017 | 61 | 0.130 |
Why?
|
| Rheumatology | 1 | 2017 | 18 | 0.130 |
Why?
|
| Interferon Type I | 1 | 2017 | 56 | 0.130 |
Why?
|
| Rheumatic Diseases | 1 | 2017 | 33 | 0.130 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2016 | 2 | 0.130 |
Why?
|
| Craniosynostoses | 1 | 2016 | 6 | 0.130 |
Why?
|
| Oklahoma | 1 | 2020 | 1038 | 0.130 |
Why?
|
| Receptors, Purinergic P2Y2 | 1 | 2016 | 3 | 0.130 |
Why?
|
| Autophagy-Related Proteins | 1 | 2016 | 9 | 0.130 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2016 | 10 | 0.120 |
Why?
|
| Aged, 80 and over | 4 | 2017 | 2045 | 0.120 |
Why?
|
| Klinefelter Syndrome | 1 | 2016 | 9 | 0.120 |
Why?
|
| Hydrocephalus | 1 | 2016 | 55 | 0.120 |
Why?
|
| Adipose Tissue | 1 | 2017 | 185 | 0.120 |
Why?
|
| Patient Selection | 1 | 2016 | 149 | 0.120 |
Why?
|
| Young Adult | 3 | 2013 | 2804 | 0.120 |
Why?
|
| Mutation, Missense | 3 | 2006 | 70 | 0.120 |
Why?
|
| Immunization, Passive | 1 | 2015 | 20 | 0.110 |
Why?
|
| Submandibular Gland | 1 | 2015 | 11 | 0.110 |
Why?
|
| Genetic Counseling | 2 | 2016 | 14 | 0.110 |
Why?
|
| Prevalence | 4 | 2019 | 510 | 0.110 |
Why?
|
| Heterozygote | 2 | 2016 | 69 | 0.110 |
Why?
|
| Lupus Nephritis | 2 | 2012 | 102 | 0.110 |
Why?
|
| Antibody Specificity | 1 | 2014 | 114 | 0.110 |
Why?
|
| Family Health | 3 | 2009 | 71 | 0.110 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 1494 | 0.110 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2016 | 72 | 0.110 |
Why?
|
| Epilepsy | 1 | 2013 | 37 | 0.100 |
Why?
|
| Adaptive Immunity | 1 | 2013 | 38 | 0.100 |
Why?
|
| Europe | 1 | 2013 | 99 | 0.100 |
Why?
|
| Genetic Loci | 1 | 2013 | 77 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 3 | 2 | 2010 | 17 | 0.100 |
Why?
|
| Genomic Instability | 1 | 2013 | 34 | 0.100 |
Why?
|
| Indians, South American | 1 | 2012 | 12 | 0.100 |
Why?
|
| Epilepsies, Myoclonic | 2 | 2003 | 2 | 0.100 |
Why?
|
| Sex Distribution | 2 | 2016 | 78 | 0.100 |
Why?
|
| Socioeconomic Factors | 2 | 2012 | 251 | 0.100 |
Why?
|
| Disease Progression | 2 | 2020 | 475 | 0.100 |
Why?
|
| Ikaros Transcription Factor | 1 | 2012 | 9 | 0.090 |
Why?
|
| Egg Proteins | 1 | 2012 | 17 | 0.090 |
Why?
|
| Molecular Motor Proteins | 1 | 2011 | 13 | 0.090 |
Why?
|
| Apolipoproteins | 1 | 2011 | 21 | 0.090 |
Why?
|
| Predictive Value of Tests | 3 | 2017 | 480 | 0.090 |
Why?
|
| Myosin Heavy Chains | 1 | 2011 | 24 | 0.090 |
Why?
|
| Lipoproteins, HDL | 1 | 2011 | 41 | 0.090 |
Why?
|
| Risk | 2 | 2013 | 137 | 0.090 |
Why?
|
| Calcium-Binding Proteins | 2 | 2009 | 62 | 0.090 |
Why?
|
| Mice | 3 | 2021 | 4732 | 0.090 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2010 | 10 | 0.080 |
Why?
|
| Aging | 1 | 2017 | 979 | 0.080 |
Why?
|
| Genetic Carrier Screening | 1 | 2009 | 10 | 0.080 |
Why?
|
| Microsatellite Repeats | 2 | 2013 | 59 | 0.080 |
Why?
|
| Cross-Cultural Comparison | 1 | 2009 | 20 | 0.080 |
Why?
|
| Apoptosis | 3 | 2021 | 777 | 0.080 |
Why?
|
| Statistics as Topic | 1 | 2009 | 79 | 0.080 |
Why?
|
| Saliva | 2 | 2021 | 96 | 0.080 |
Why?
|
| Sex Factors | 1 | 2010 | 467 | 0.070 |
Why?
|
| Retrospective Studies | 2 | 2019 | 2612 | 0.070 |
Why?
|
| Anxiety | 1 | 2010 | 157 | 0.070 |
Why?
|
| Antirheumatic Agents | 2 | 2019 | 57 | 0.070 |
Why?
|
| RNA, Small Cytoplasmic | 2 | 2019 | 63 | 0.070 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 2 | 2004 | 31 | 0.070 |
Why?
|
| Algorithms | 1 | 2010 | 430 | 0.070 |
Why?
|
| Depression | 1 | 2010 | 222 | 0.070 |
Why?
|
| Microsatellite Instability | 1 | 2007 | 10 | 0.070 |
Why?
|
| Trinucleotide Repeats | 1 | 2007 | 14 | 0.070 |
Why?
|
| Apolipoprotein E4 | 1 | 2007 | 20 | 0.070 |
Why?
|
| Follow-Up Studies | 1 | 2010 | 1026 | 0.070 |
Why?
|
| Gene Dosage | 2 | 2017 | 35 | 0.070 |
Why?
|
| Cerebellar Ataxia | 1 | 2006 | 2 | 0.070 |
Why?
|
| Trisomy | 2 | 2017 | 19 | 0.070 |
Why?
|
| Ganglia, Spinal | 1 | 2007 | 25 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2017 | 257 | 0.060 |
Why?
|
| Autoantigens | 2 | 2019 | 212 | 0.060 |
Why?
|
| Immunoprecipitation | 2 | 2017 | 68 | 0.060 |
Why?
|
| Computational Biology | 2 | 2021 | 156 | 0.060 |
Why?
|
| Parkinson Disease | 1 | 2007 | 47 | 0.060 |
Why?
|
| Presenilin-1 | 1 | 2006 | 4 | 0.060 |
Why?
|
| HLA-DQ beta-Chains | 2 | 2016 | 14 | 0.060 |
Why?
|
| Founder Effect | 1 | 2006 | 6 | 0.060 |
Why?
|
| Infant | 1 | 2010 | 1019 | 0.060 |
Why?
|
| Complementarity Determining Regions | 1 | 2025 | 11 | 0.060 |
Why?
|
| Bayes Theorem | 2 | 2017 | 100 | 0.060 |
Why?
|
| Cerebellar Neoplasms | 1 | 2006 | 30 | 0.060 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2016 | 75 | 0.060 |
Why?
|
| DNA | 2 | 2004 | 375 | 0.060 |
Why?
|
| Nuclear Proteins | 1 | 2007 | 249 | 0.060 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2025 | 117 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 2 | 2016 | 244 | 0.060 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2025 | 82 | 0.060 |
Why?
|
| Gene Expression Regulation | 2 | 2019 | 633 | 0.060 |
Why?
|
| Sequence Analysis, DNA | 3 | 2013 | 376 | 0.060 |
Why?
|
| Signal Transduction | 2 | 2021 | 1454 | 0.050 |
Why?
|
| Oxygen Consumption | 1 | 2025 | 181 | 0.050 |
Why?
|
| Linear Models | 2 | 2017 | 202 | 0.050 |
Why?
|
| OX40 Ligand | 2 | 2016 | 16 | 0.050 |
Why?
|
| STAT4 Transcription Factor | 2 | 2016 | 23 | 0.050 |
Why?
|
| Molecular Sequence Data | 4 | 2009 | 1056 | 0.050 |
Why?
|
| Spinocerebellar Degenerations | 1 | 2003 | 1 | 0.050 |
Why?
|
| Alzheimer Disease | 1 | 2006 | 223 | 0.050 |
Why?
|
| Basal Ganglia Diseases | 1 | 2003 | 3 | 0.050 |
Why?
|
| CD11b Antigen | 2 | 2016 | 42 | 0.050 |
Why?
|
| Olfaction Disorders | 1 | 2003 | 4 | 0.050 |
Why?
|
| Energy Metabolism | 1 | 2025 | 206 | 0.050 |
Why?
|
| T-Lymphocytes | 1 | 2025 | 285 | 0.050 |
Why?
|
| Vimentin | 1 | 2023 | 28 | 0.050 |
Why?
|
| Granuloma | 1 | 2022 | 18 | 0.050 |
Why?
|
| Lafora Disease | 1 | 2002 | 5 | 0.050 |
Why?
|
| Genetic Variation | 2 | 2013 | 245 | 0.050 |
Why?
|
| Animals | 4 | 2021 | 10580 | 0.050 |
Why?
|
| Chromosome Mapping | 3 | 2012 | 128 | 0.050 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2002 | 38 | 0.050 |
Why?
|
| Mannose-Binding Protein-Associated Serine Proteases | 1 | 2021 | 5 | 0.050 |
Why?
|
| Parotid Gland | 1 | 2021 | 6 | 0.050 |
Why?
|
| ADAM17 Protein | 1 | 2021 | 13 | 0.050 |
Why?
|
| DNA-Binding Proteins | 2 | 2016 | 490 | 0.050 |
Why?
|
| Thymocytes | 1 | 2021 | 13 | 0.050 |
Why?
|
| Mice, Inbred NOD | 1 | 2021 | 50 | 0.040 |
Why?
|
| Histone Code | 1 | 2021 | 4 | 0.040 |
Why?
|
| Polymorphism, Genetic | 3 | 2007 | 166 | 0.040 |
Why?
|
| Clonal Anergy | 1 | 2020 | 11 | 0.040 |
Why?
|
| Age Factors | 2 | 2017 | 734 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2020 | 82 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2020 | 61 | 0.040 |
Why?
|
| Information Dissemination | 1 | 2020 | 37 | 0.040 |
Why?
|
| Genetics, Population | 2 | 2013 | 72 | 0.040 |
Why?
|
| Histological Techniques | 1 | 2019 | 8 | 0.040 |
Why?
|
| Sialography | 1 | 2019 | 1 | 0.040 |
Why?
|
| Epistaxis | 1 | 2019 | 7 | 0.040 |
Why?
|
| Ichthyosis | 1 | 2019 | 6 | 0.040 |
Why?
|
| Genetic Heterogeneity | 2 | 2013 | 31 | 0.040 |
Why?
|
| Fibromyalgia | 1 | 2019 | 13 | 0.040 |
Why?
|
| Deglutition Disorders | 1 | 2019 | 24 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2019 | 75 | 0.040 |
Why?
|
| Interferons | 1 | 2019 | 70 | 0.040 |
Why?
|
| Linkage Disequilibrium | 2 | 2011 | 108 | 0.040 |
Why?
|
| Macrophages | 1 | 2021 | 302 | 0.040 |
Why?
|
| Treponema denticola | 1 | 2018 | 6 | 0.040 |
Why?
|
| Porphyromonas gingivalis | 1 | 2018 | 7 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2021 | 861 | 0.040 |
Why?
|
| Glycosylation | 1 | 2018 | 70 | 0.040 |
Why?
|
| Models, Biological | 1 | 2020 | 468 | 0.040 |
Why?
|
| United States Virgin Islands | 1 | 2017 | 4 | 0.030 |
Why?
|
| British Virgin Islands | 1 | 2017 | 4 | 0.030 |
Why?
|
| Puerto Rico | 1 | 2017 | 6 | 0.030 |
Why?
|
| Karyotype | 1 | 2017 | 3 | 0.030 |
Why?
|
| Hydroxychloroquine | 1 | 2017 | 20 | 0.030 |
Why?
|
| Turner Syndrome | 1 | 2017 | 7 | 0.030 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2017 | 50 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2017 | 95 | 0.030 |
Why?
|
| ROC Curve | 1 | 2017 | 144 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 2017 | 48 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2018 | 210 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2017 | 24 | 0.030 |
Why?
|
| Virus Diseases | 1 | 2017 | 39 | 0.030 |
Why?
|
| Fibrosis | 1 | 2017 | 134 | 0.030 |
Why?
|
| Spatial Analysis | 1 | 2016 | 8 | 0.030 |
Why?
|
| Datasets as Topic | 1 | 2016 | 22 | 0.030 |
Why?
|
| Internationality | 1 | 2016 | 31 | 0.030 |
Why?
|
| Eye Diseases | 1 | 2016 | 31 | 0.030 |
Why?
|
| Logistic Models | 1 | 2017 | 409 | 0.030 |
Why?
|
| Republic of Korea | 1 | 2016 | 11 | 0.030 |
Why?
|
| Chromosomes, Human, Y | 1 | 2016 | 9 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2021 | 1601 | 0.030 |
Why?
|
| Tumor Necrosis Factor alpha-Induced Protein 3 | 1 | 2016 | 24 | 0.030 |
Why?
|
| Mitochondrial Proton-Translocating ATPases | 1 | 2016 | 8 | 0.030 |
Why?
|
| Argentina | 1 | 2016 | 9 | 0.030 |
Why?
|
| Chile | 1 | 2016 | 9 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2016 | 11 | 0.030 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2016 | 14 | 0.030 |
Why?
|
| Hypergammaglobulinemia | 1 | 2016 | 7 | 0.030 |
Why?
|
| HLA-DQ Antigens | 1 | 2016 | 25 | 0.030 |
Why?
|
| Peru | 1 | 2016 | 31 | 0.030 |
Why?
|
| Tripartite Motif Proteins | 1 | 2016 | 8 | 0.030 |
Why?
|
| Sulfur Radioisotopes | 1 | 2016 | 10 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2016 | 51 | 0.030 |
Why?
|
| Methionine | 1 | 2016 | 38 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 216 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 524 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2017 | 290 | 0.030 |
Why?
|
| Quality of Life | 1 | 2019 | 504 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 834 | 0.030 |
Why?
|
| Lip | 1 | 2014 | 10 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2018 | 815 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 782 | 0.030 |
Why?
|
| CpG Islands | 1 | 2014 | 26 | 0.030 |
Why?
|
| Ataxin-10 | 1 | 2013 | 1 | 0.030 |
Why?
|
| Asian Americans | 1 | 2013 | 40 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 994 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2013 | 126 | 0.030 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2013 | 58 | 0.030 |
Why?
|
| Evolution, Molecular | 1 | 2013 | 85 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 272 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2014 | 344 | 0.020 |
Why?
|
| Morbidity | 1 | 2012 | 58 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2013 | 452 | 0.020 |
Why?
|
| Apolipoprotein L1 | 1 | 2011 | 10 | 0.020 |
Why?
|
| Latin America | 1 | 2010 | 9 | 0.020 |
Why?
|
| Cytosine | 1 | 2010 | 6 | 0.020 |
Why?
|
| Guanine | 1 | 2010 | 25 | 0.020 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2010 | 16 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2010 | 104 | 0.020 |
Why?
|
| Family | 1 | 2010 | 98 | 0.020 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2010 | 77 | 0.020 |
Why?
|
| Exons | 1 | 2009 | 42 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 2010 | 101 | 0.020 |
Why?
|
| Embryonic Development | 1 | 2007 | 22 | 0.020 |
Why?
|
| Apolipoproteins E | 1 | 2006 | 45 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 328 | 0.020 |
Why?
|
| Genes, Recessive | 1 | 2004 | 21 | 0.010 |
Why?
|
| Japan | 1 | 2004 | 23 | 0.010 |
Why?
|
| Homozygote | 1 | 2004 | 36 | 0.010 |
Why?
|
| North America | 1 | 2004 | 41 | 0.010 |
Why?
|
| Disease Transmission, Infectious | 1 | 2004 | 6 | 0.010 |
Why?
|
| Germ Cells | 1 | 2004 | 15 | 0.010 |
Why?
|
| Age Distribution | 1 | 2004 | 73 | 0.010 |
Why?
|
| Mouth Mucosa | 1 | 2004 | 16 | 0.010 |
Why?
|
| Spermatozoa | 1 | 2004 | 34 | 0.010 |
Why?
|
| Leukocytes | 1 | 2004 | 72 | 0.010 |
Why?
|
| Smell | 1 | 2003 | 13 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2004 | 163 | 0.010 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2003 | 98 | 0.010 |
Why?
|
| Time Factors | 1 | 2007 | 1600 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2002 | 92 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2002 | 26 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2002 | 46 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatases, Non-Receptor | 1 | 2002 | 20 | 0.010 |
Why?
|
| Cell Line | 1 | 2004 | 698 | 0.010 |
Why?
|
| Intellectual Disability | 1 | 2002 | 16 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2003 | 247 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2002 | 208 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2004 | 1009 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 588 | 0.010 |
Why?
|
| Gene Expression | 1 | 2002 | 417 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2002 | 515 | 0.010 |
Why?
|